StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Therapeutic Area Revenue Growth at Constant Currencies by Quarter

Therapeutic Area Revenue Growth at Constant Currencies (% cc) (%)

QuarterlyAnnual

Novartis Therapeutic Area Revenue Growth at Constant Currencies: 10.0% in Q3 2026, up 6.0 pts from a year earlier.

Latest, Q3 2026
10.0%
Period ended Sep 30, 2026
Change on a year earlier
+6.0 pts
4.0% in Q3 2025
History
12 quarters
Since Q4 2023
Sources
12
Documents cited below

Where the Q3 2026 figure comes from

“|| Total immunology | 2 880 | 2 611 | 10 | 10”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTherapeutic Area Revenue Growth at Constant Currencies (% cc) (%)Year on yearSource
Q3 2026Sep 30, 202610.0%+6.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20268.0%-1.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026-1.0%-19.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202511.0%-8.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20254.0%-19.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 20259.0%-13.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 202518.0%-3.0 ptsNovartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 202419.0%-2.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 202423.0%–Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 202422.0%–Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 202421.0%–Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 202321.0%–Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Therapeutic Area Revenue Growth at Constant Currencies (%), quarterly Q4 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-immunology-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.